Sepsis
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. According to the sepsis-3.0 criteria jointly released by the Society of Critical Care Medicine (SCCM) in the United States and the European Society of Intensive Care Medicine (ESICM) in 2021, sepsis is clearly diagnosed. 2. The diagnosis of SAE (Sepsis-Associated Encephalopathy): SAE is defined as a Glasgow Coma Scale (GCS) score <15 in sepsis patients, or the presence of delirium (including inattention, disorientation, altered thinking, psychomotor retardation and/or agitation) in medical records. Delirium is assessed twice a day, in the morning and evening, and the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) is used as the standard for diagnosing SAE. Other causes affecting neurological function should be excluded, including drug effects, metabolic disorders, primary central nervous system diseases (such as meningitis, encephalitis, cerebrovascular disease, epilepsy, etc.) and non-infectious systemic inflammatory responses (such as burns, severe pancreatitis, trauma, etc.). Patients are divided into SAE group and non - SAE group according to the disease progression. 3. The patient is admitted to the ICU for the first time and the duration of ICU stay is more than 72 hours. 4. The subject has the ability to understand this study and is willing to participate in it, and has signed the informed consent form. For subjects without the capacity to act, if the investigator believes that the subject's participation in the trial is in his/her own interest, the informed consent form should be signed by his/her legal guardian and explained in the original medical records and other relevant documents.
Exclusion criteria
Exclusion criteria: 1.Patients with primary central nervous system diseases, intracranial infections, trauma, vascular dementia, Alzheimer's disease, and other diseases that affect consciousness and mental state; 2.Acute brain injury as the reason for ICU admission (such as meningitis, encephalitis, status epilepticus, traumatic brain injury, or stroke); 3.Other diseases affecting consciousness, such as hepatic encephalopathy; 4.According to the investigator's judgment, any physical examination findings, laboratory abnormalities, and/or any medical history of the subject may endanger their safety due to participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Differential serum metabolites represented by 4-hydroxyphenylacetic acid; | — |
Secondary
| Measure | Time frame |
|---|---|
| The assay index represented by lactic acid; | — |
Countries
China
Contacts
Xijing Hospital, the First Affiliated Hospital of PLA Air Force Medical University